Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine metronomic maintenance therapy after NED in metastatic colorectal cancer
ChiCTR2100047149Phase 4Recruiting
- Sponsor
- Zhongshan Hospital of Traditional Chinese Medicine
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in metastatic colon cancer (mCRC) comparing Capecitabine metronomic maintenance with Watch-and-wait observation (2 arms). Primary endpoint: progression-free survival. Started Jul 2021; status: recruiting.
02
Drugs
capecitabine
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on ChiCTR2100047149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047149.